Antifolates - Past, Present and Future

By  

Current Medicinal Chemistry - Anti-Cancer Agents, Vol. 4, Iss. 5, 2004-09 ,pp. : 405-410

Bentham Science Publishers

Access to resources Recommend Favorite

Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma

By Srkalovic Gordan   Elson Paul   Trebisky Beth   Karam Mary   Hussein Mohamad  

Medical Oncology, Vol. 19, Iss. 4, 2002-12 ,pp. : 219-226

Humana Press, Inc

Access to resources Recommend Favorite

Response of plasmacytomas to low-dose thalidomide in a patient with refractory multiple myeloma

By Ribas Christian   Colleoni Gisele   Almeida Manuella   Duch Cibele Repele   Ohashi Cláudio   Segreto Roberto   Silva Maria Regina  

Acta Oncologica, Vol. 43, Iss. 2, 2004-03 ,pp. : 215-216

Informa Healthcare

Access to resources Recommend Favorite

Randomized Phase II Trial of Thalidomide Alone versus Thalidomide Plus Interferon Alpha in Patients with Refractory Multiple Myeloma

By Chiou Tzeon-Jye   Wang Teng-Hsu   Chao Tsu-Yi   Lin Sheng-Fung   Tang Jih-Luh   Chen Tsai-Yun   Chang Ming-Chih   Hsueh Erh-Jung   Chen Po-Min  

Cancer Investigation, Vol. 25, Iss. 3, 2007-04 ,pp. : 140-147

Informa Healthcare

Access to resources Recommend Favorite

The Human Environment: Past, Present and Future

By Sztanyik L.B.  

International Journal of Radiation Biology, Vol. 46, Iss. 1, 1984-07 ,pp. : 96-97

Informa Healthcare

Access to resources Recommend Favorite